Publication

1)     Stian Foss, Siri A. Sakya, Leire Aguinagalde, Marta Lustig, Jutamas Shaughnessy, Ana RitaCruz, Lisette Scheepmaker, Line Mathiesen, Fulgencio Ruso Julve, Torleif Tollefsrud Gjølberg, Simone Mester, Malin C. Bern,Mitchell Evers, Diane B. Bratlie, Terje E. Michaelsen, Tilman Schlothauer, Devin Sok, Jayanta Bhattacharya, Jeanette Leusen, Thomas Valerius, Sanjay Ram, Suzan H.M. Rooijakkers, Inger Sandlie and Jan Terje Andersen*. (2024); IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria. Nat Commun. 15 (1): 2007.

2)     Clayton Fernando Rencilin, Mohammad Yousuf Ansari, Arnab Chatterjee, Suprit Deshpande, Sohini Mukherjee, Randhir Singh, Sowrabha Jayatheertha, Poorvi M. Reddy, Payel Das, Nitin Hingankar, Deepak Rathore, Raghavan Varadarajan, Jayanta Bhattacharya*, Somnath Dutta* (2022). Structural insights and conformational states of two potent and broadly neutralizing human monoclonal antibodies bound to SARS-CoV-2 trimeric spike protein. bioRxiv 2022.12.03.518949; doi: https://doi.org/10.1101/2022.12.03.518949.

3)     Deshpande, S.,  Mohammed Yousuf Ansari, Jyoti Sutar, Payel Das, Nitin Hingankar, Sohini Mukherjee, Priyanka Jayal, Savita Singh, Anbalagan Anantharaj, Janmejay Singh, Souvick Chattopadhyay, Sreevatsan Raghavan, Mudita Gosain, Supriya Chauhan, Shweta Shrivas, Chaman Prasad, Sangeeta Chauhan, Neha Sharma, Pradipta Jana, Ramachandran Thiruvengadam, Pallavi Kshetrapal, Nitya Wadhwa, Bhabatosh Das, Gaurav Batra,  Guruprasad Medigeshi, Devin Sok, Shinjini Bhatnagar, Pramod Kumar Garg, Jayanta Bhattacharya* (2023). Ancestral SARS-CoV-2 driven antibody repertoire diversity in an unvaccinated individual correlates with expanded neutralization breadth. Microbiology Spectrum Mar 22;11(2): e0433222.

4)     Gaurav Batra, Deepika Rathna Murugesan, Souvick Chattopadhyay, Farha Mehdi, Ayushi, Mudita Gosain, Savita Singh, Soon Jyoti Das, Suprit Deshpande, Jayanta Bhattacharya, Anil K, Pandey, Sankalp Jha, Shweta Goswami, Asim Das, Tanima Dwivedi, Nandini Sharma, Suresh Kumar, Pragya Sharma, Seema Kapoor, Pallavi Kshetrapal, Nitya Wadhwa, Ramachandran Thiruvengadam, Rakesh Kumar, Ritu Gupta, Pramod Kumar Garg*, Shinjini Bhatnagar *, for DBT Consortium for COVID-19 Research (2022). Long-term Durable Humoral Immune Response to Heterologous Antigenic Exposure Post six months by natural SARS-CoV-2 Infection and Vaccination. Indian J Med Res. 57(6):509-518

5)     Hingankar, K., Deshpande, S., Das, P., Rizvi, Z.A., Wibmer, C.K., Mashilo, P., Burns, A., Barman, S., Zhao, F., Ansari, M.Y., Mukherjee, S., Torres, J. T., Chattopadhyay, S., Mehdi, F., Sutar, J., Rathore, D.K., Pargai, K., Singh, J., Sonar, S., Jakhar, K., Bhattacharyya, S., Mani, S., samal, S.., Singh, S., Dandotiya, J., Kshetrapal, P., Thiruvengadam, R., Batra, G., Medigeshi, G.R, Ward, A., Bhatnagar, S.,  Awasthi, A., Sok, D.*, Bhattacharya, J.*. (2022). Potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against SARS-CoV-2 Delta. PLOS Pathogens Apr 28;18(4): e1010465

6)     Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Srivastava, T., Samal, S., Murugesan, D. R., Desiraju, B. K., Kshetrapal, P., Pandey, R., Scaria, V., Kumar, P., Taneja, J., Akshay and Vohra, Tarini and Zaheer, Aymaan and Rathore, Deepak, Khan, Naseem Ahmed, Shaman, Heena, Ahmed, Shubbir, Kumar, Rajesh,  Deshpande, Suprit, Subramani, Chandru, Wadhwa, Nitya, Gupta, Nimesh, Pandey, Anil K., Bhattacharya, Jayanta, Agrawal, Anurag, Vrati, Sudhanshu, Bhatnagar, Shinjini, Garg, Pramod Kumar and COVID-19 Research, DBT Consortium (2022). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative case-control study and a Mechanistic Study of Post-Vaccination Immune Responses. Lancet Infect Dis. (Apr;22(4):473-482.

7)     Mullick, R., Sutar, J., Hingankar, N., Deshpande, S., Thakar, M., Sahay, S., Ringe, R.P., Mukhopadhyay, S., Patil, A., Bichare, S., Murugavel, K.G., Srikrishnan, A.K., Goyal, R., Sok, D. Bhattacharya, J.* (2021). Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities. Retrovirology 18: 12

8)     Sutar, J; Deshpande, S; Mullick, R, Hingankar, N., Patel, V., Bhattacharya, J*. (2021). Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivityPLOS ONE.16(5): e0251969.

9)     Kumar, R., Deshpande, S., Sewall, L.M., Ozorowski, G., Cottrell, C.A., Lee, W., Holden, L.G., Richey, S.T., Chandrawacar, A.S., Dhiman, K., Ashish, Kumar, V., Ahmed, S., Hingankar, N., Kumar, N., Murugavel, K.G., Srikrishnan, A.K., Sok, D., Ward, A.B.,Bhattacharya, J.* (2021). Elicitation of potent serum neutralizing antibody responses in rabbits by immunization with an HIV-1 clade C trimeric Env derived from an Indian elite neutralizer. PLOS Pathogens17 (4): e1008977.

10)   Sutar, J., Padwal., V., Sonawani, A., Nagar, V., Patil, P, Kulkarni, B., Hingankar, N., Deshpande, S., Idicula-Thomas, S., Jagtap, J., Bhattacharya, J., Bandivdekar, A., Patel, V. (2019). Effect of diversity in gp41 membrane proximal external region of primary HIV-1 Indian subtype C sequences on interaction with broadly neutralizing antibodies 4E10 and 10E8. Virus Res. 273: 197763.

11)   Pergu, R., Dagar, S., Kumar, H., Kumar, R., Bhattacharya, J., and Mylavarapu, SVS (2019). The chaperone ERp29 is required for tunneling nanotube formation by stabilizing MSec. J Biol. Chem. May 3;294(18):7177-7193.

12)   Bhattacharya, J.(2019). HIV prevention & treatment strategies - Current challenges & future prospects (EDITORIAL). Indian J Med Res. 148, December 2018, pp: 671-674

13)   Kumar, R., Qureshi, H., Deshpande, S., Bhattacharya, J* (2018). Broadly neutralizing antibodies in HIV-1 treatment and prevention. Therapeutic Advances in Vaccines and Immunotherapy 6 (4): 61-68.

14)   Das, S.*, Bansal, M., Bhattacharya, J. (2018). Characterization of the membrane-bound form of the chimeric, B/C recombinant HIV-1 Env, LT5.J4b12C. J Gen. Virol 99 (10): 1438-1443

15)   Paneerselvam, N., Bhattacharya, J., Srikrishnan, A.K., Goyal, R., Ravichandran, S.C., Patil, S., Saravanan, S., Deshpande, S., Ramachandran, V., Solomon, S.S., Singla, N., Mukherjee, J., Murugavel, K.G. (2018). Broad Neutralization Response in a Subset of HIV-1 Subtype C infected Viremic Non-Progressors from Southern India. J Gen. Virol. 99: 379-393

16)   Kumar, R., Ozorowski, G., Kumar, V., Holden, L., Shrivastava, T., Patil, S., Deshpande, S., Ward, A.B., Bhattacharya, J*. (2017). Characterization of a stable HIV-1 B/C recombinant, soluble and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes. Journal of Biological Chemistry. 292 (38): 15849-15858

17)   Qureshi, H. and Bhattacharya, J.* (2017). Dual immunity concomitantly suppresses HIV-1 progression. Trends in Microbiol. 25 (5): 334-335.

18)   Khan, L., Kumar, R., Thiruvengadam, R., Parray, H.A., Makhdoomi, M.A., Kumar, S., Aggarwal, H., Mohata, M., Hussain, A.W., Das, R., Varadarajan, R., Bhattacharya, J., Vajpayee, M., Murugavel, K.G., Solomon, S., Sinha, S., Luthra, K.* (2017). Cross-neutralizing anti-HIV-1 human single chain variable fragments (scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library. Scientific Reports. Mar 23; 7: 45163.

19)   Deshpande, S., Patil, S., Kumar, R., Shrivastava, T., Srikrishnan, A.K., Murugavel, K.G., Koff, W.C., Chakrabarti, B.K., Bhattacharya, J*. (2016). Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies. Retrovirology 13: 41

20)   Despande, S., Patil, S., Kumar, R., Hermanus, T., Murugavel, K.G., Solomon, S., Morris, L., Bhattacharya, J*.(2016)HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms. Retrovirology30;13(1):60

21)   Patil, S., Kumar, R., Deshpande, S., Samal, S., Shrivastava, T., Boliar, S., Bansal, M., Chaudhary, N.K., Srikrishnan, A.K., Murugavel, K.G., Solomon, S., Simek, M., Koff, W.C., Goyal, R., Chakrabarti, B.K., Bhattacharya, J.*(2016). Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C Infected Elite Neutralizer Mediate Autologous Virus Escape through Novel Mutations in V1 Loop. Journal of Virology 90 (7):3446-3457.

22)   Khan, L., Makhdoomi, M.A., Kumar S., Nair, A., Andrabi, R., Clark, B.E., Auyeung, K., Bhattacharya, J., Vajpayee, M., Wig, N., Pantophlet, R., Luthra, K. (2015). Identification of CD4-binding site dependent plasma neutralizing antibodies in an HIV-1 infected Indian individual PLoS One 10(5):e0125575

23)   Boliar S, Das, S., Bansal, M., Shukla, B.N., Patil, S., Shrivastava, T., Samal, S., Goswami, S., King, C.R., Bhattacharya, J., Bimal K Chakrabarti (2015). An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies. PLoS One 10(3): e0122443

24)   SV Kulkarni, M Bala, J Bhattacharya, A Risbud. (2015). Detection of mutations in mtrR gene in quinolone resistant strains of N.gonorrhoeae isolated from India. Indian Journal of Medical Microbiology, 33(2): 277-281

25)   Patil, S., Choudhary, I., Chaudhary, N., Ringe, R, Bansal, M, Shukla, B.N., Boliar, S., Chakrabarti, B.K., and Bhattacharya, J.* (2014). Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in context dependent manner. Virology 462-463: 266–272

26)   Tilghman MW, Bhattacharya J., Deshpande S, Ghate M, Espitia S, Grant I, Marcotte TD, Smith D, Mehendale S. (2014). Genetic attributes of blood-derived subtype-C HIV-1 tat and env in India and neurocognitive function. J Med Virol. 86(1): 88-96

27)   Mahajan S.D, Gaekwad A, Pawar J, Tripathy S, Ghate M, Bhattacharya J, Singh HO, Schwartz SA, Paranjape R, Gangakhedkar R. (2014). Cardiac Morbidity in an HIV-1 Lipodystrophy Patient Cohort Expressing the TNF-α-238 G/A Single Nucleotide Gene Polymorphism. Curr HIV Res. 13: 98-108

28)   Ringe, R. and Bhattacharya, J.* (2013). Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1. Therapeutic Adv in Vaccines. 1: 67-80

29)   Gautam, A. and Bhattacharya, J.*(2013). Evidence that Vpu Modulates HIV-1 Gag-Envelope Interaction towards Envelope Incorporation and Infectivity in a Cell Type Dependent Manner. PLoS One 8(4): e61388

30)   Ghate M, Tripathy S, Gangakhedkar R, Thakar M, Bhattacharya J, Choudhury I, Risbud A, Bembalkar S, Kadam D, Rewari BB, Paranjape R. (2013). Use of first line antiretroviral therapy from a free ART programme clinic in Pune, India - A preliminary report. Indian J Medical Research 137(5):942-9

31)   Choudhary, I., Chimanpure, V., Patil, A., and Bhattacharya, J.* (2013).Single step detection of HIV-1 proviral DNA and housekeeping β-actin gene from dried blood spots by monoplex polymerase chain reaction. J Virol Methods 187: 203-206.

32)   Kulkarni S, Bala M, Sane S, Pandey S, Bhattacharya J, Risbud A. (2012). Mutations in the gyrA and parC genes of quinolone-resistant Neisseria gonorrhoeae isolates in India. Int J Antimicrob Agents. 40(6):549-53

33)   Patil, A. and Bhattacharya, J.* (2012). Natural deletion of L35Y36 in p6 gag eliminate LYPXnL/ALIX auxiliary virus release pathway in HIV-1 subtype C. Virus Research 170: 154-158

34)   Gautam, A.*, Patil, A. and Bhattacharya, J. (2012). Gag-Vpu cross talk modulating HIV-1 envelope incorporation and infectivity in cell-type dependent manner. BMC Infectious Diseases 12 (Suppl 1): P49       

35)   Ringe, R., Das, L., Choudhury, I., Sharma, D., Paranjape, R., Chauhan, V.S., and Bhattacharya, J.* (2012). Unique sequence pattern in the C2V3 region in HIV-1 envelope obtained from broadly neutralizing plasma of an antiretroviral naïve chronically infected patient conferred enhanced neutralization by exposition of discontinuous neutralizing epitopes. PLoS One7(10):e46713.

36)   Ringe, R., and Bhattacharya, J.* (2012).Association of enhanced HIV-1 neutralization by a single residue substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity. PLoS One 7(5): e37157

37)   Ringe, R., Phogat, S. and Bhattacharya, J*. (2012). Subtle alteration of residues including N-linked glycans in V2 loop modulates HIV-1 neutralization by PG9 and PG16 monoclonal antibodies. Virology 426: 34–41

38)   Gharu, L., Ringe, R., and Bhattacharya, J.* (2012). Evidence of extended alternate coreceptor usage by HIV-1 clade C envelope obtained from an Indian patient. Virus Research 163 (2012) 410–414

39)   Ringe, R., Sharma, D., Zolla-Pazner, S., Phogat, S., Risbud, A., Thakar, M., Paranjape, R and Bhattacharya, J.* (2011)A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop, Virology 418: 123–132

40)   Gharu, L., Ringe, R., and Bhattacharya, J*. (2011). HIV-1 clade C envelopes obtained from late stage symptomatic Indian patients varied in their ability towards relative CD4 usages and sensitivity to CCR5 antagonist TAK-779. Virus Research 158: 216–224

41)   Mukhopadhyay, S., Ringe, R., Patil, A., Paranjape, R and Bhattacharya, J*. (2011) Characterization of circulating HIV-1 env genes in plasma of two antiretroviral naïve slow progressing patients with broad neutralizing antibody response with evidence of recombination. AIDS Res Human Retroviruses28(7):739-45.

42)   Jadhav, S., Tripathy, S., Kulkarni, S., Chaturbhuj, D., Ghare, R., Bhattacharya, J.* and Paranjape, R. (2011) Genetic conservation in gp36 transmembrane sequences of Indian HIV-2 isolates. AIDS Res Human Retroviruses (May 19. [Epub ahead of print] PMID: 21453135)

43)   Gharu, L., Ringe, R., Anupindi S., Patil, A and Bhattacharya, J.* (2011). Evidence of HIV-1 clade C env clones containing low V3 loop charge obtained from an AIDS patient in India that uses CXCR6 and CCR8 for entry in addition to CCR5. AIDS Res Human Retroviruses 27 (2): 211-219

44)    Ringe, R., Thakar, M. and Bhattacharya, J.* (2010). Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade 1 C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection. Retrovirology 7:76

45)   Sharma, D. and Bhattacharya, J.* (2010) Evolutionary constraints acting on DDX3X protein potentially interferes with Rev-mediated nuclear export of HIV-1 RNA. PLoS One 5(3): e9613.

46)   Patil, A., Gautam, A and Bhattacharya, J.* (2010) Evidence that Gag facilitates HIV-1 envelope association both in GPI-enriched plasma membrane and detergent resistant membranes and facilitates envelope incorporation onto virions in primary CD4+ T cells. Virology J7: 3

47)   Sharma, D. and Bhattacharya, J.* (2009). Dynamics of evolution of HIV-1 Rev binding host factors with their predicted role in HIV associated neuropathogenesis. Journal of Neurovirology, 15 (Supplementary 1): 88-89 (DOI: 10.1080/13550280903016074)

48)   Gharu, L., Ringe, R., Pandey, S., Paranjape, S., and Bhattacharya, J.* (2009). HIV-1 clade C env clones obtained from an Indian patient exhibiting expanded coreceptor tropism are presented with naturally occurring unusual amino acid substitutions in V3 loop. Virus Research 144:306-314.

49)    Sharma, D and Bhattacharya, J.* (2009). Cellular and Molecular Basis of HIV-Associated Neuropathogenesis. Indian Journal of Medical Research 129: 637-651

50)   Ringe, R., Gharu, R., Satyakumar, A., Pandey, S., Thakar, M. and Bhattacharya, J *. (2008). Genetic and Neutralization Properties of HIV-1 India Clade C Envelope in Recent Infection: Correlation with CCR5 Usage and Clonal Divergence. AIDS Res Human Retrovirus 24 Supplement 1: 33-33. (DOI: 10.1089/aid.2008.9997a).

51)   The Six Week Extended Dose Nevirapine (SWEN) Study Team (2008). Extended Dose of Nevirapine to Six Weeks of Age for Infants in Ethiopia, India and Uganda: A Randomized Trial for Prevention of HIV Transmission through Breastfeeding. Lancet 372: 300-313

52)   Lakhashe, S., Tripathy, S.P., Paranjape, R.S. and Bhattacharya, J.* (2008). Evidence of a Novel B/C Recombinant Exhibiting Unique Breakpoints of Nearly Full Length HIV-1 Genome in North Eastern India. AIDS Res Human Retroviruses 24 (2): 229-234

53)   Lakhashe, S., Tripathy, S.P., Paranjape, R.S. and Bhattacharya, J.* (2008). Characterization of B/C Recombinants of Nearly Full Length HIV-1 in North Eastern India with Mosaics Identical to ARE195FL but with a Different Ancestral Origin. AIDS Res Human Retroviruses 24 (1): 92-99

54)   Peters P.J., Sullivan, W.M, Duenas Decamp, M., Bhattacharya, J., Ankghuambom, C., Brown, R., Luzuriaga, K., Bell, J., Simmonds, P., Ball, J and Clapham, P.R. (2006). Macrophage-tropic R5 envelopes are infrequent in blood, lymph nodes and semen: Implications for transmission and pathogenesis. Journal of Virology 80: 6324-6332

55)   Bhattacharya, J., Repik, A. and Clapham, P.R. (2006). Gag regulates Human Immunodeficiency virus type 1 envelope association with detergent resistant membranes. Journal of Virology 80: 5292-5300

56)   Bhattacharya, J., Peters, P.J., and Clapham, P.R. (2004). Human Immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: Impact on association with membrane lipid rafts and incorporation onto budding virus particles. Journal of Virology, 8: 5500-5506.

57)   Bhattacharya, J.,* Peters, P.J.,* Hibbitts, S.,* Dittmar, M.T., Simmons, G.S, Bell, J., Simmonds, P.S. and Clapham, P.R. (2004). Biological analysis of HIV-R5 envelopes amplified from brain and lymph node tissue of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in brain that confer an enhanced tropism and fusigenicity for macrophages. Journal of Virology 78: 6915-6926 [* equal contribution].

58)   Bhattacharya, J., Peters, P. J., and Clapham, P.R. (2003). CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo. AIDS: S35-S43.

59)   Bhattacharya, J., Samanta, S., Hoque, K.M., Mukherjee, A. and Chakrabarti, M.K. (2001). Escherichia coli heat stable enterotoxin receptors and guanylyl cyclase activity in the intestinal brush border membrane of hamsters and guinea pigs. Indian Journal of Medical Research, 113; 5-10

60)   Bhattacharya, J. and Chakrabarti, M.K. (1999). Binding of Escherichia coli heat stable toxin and rise of guanylyl cyclase activity in the brush border membranes of rabbit intestinal epithelial cells. Journal of Diarrhoeal Diseases Research; 1; 28-33.

61)   Basu, I., Mitra, R., Saha, P.K., Ghosh, A.N., Bhattacharya, J., Chakrabarti, M.K., Takeda, Y. and Nair G.B. (1999). Morphological and cytoskeletal changes caused by non-membrane damaging cytotoxin of Vibrio cholerae on INT 407 and HeLa cells. FEMS Microbiology Letters. 179(2): 255-63.

62)   Bhattacharya, J. and Chakrabarti, M.K. (1998). Rise of intracellular free calcium levels with activation of inositol triphosphate in a human colonic carcinoma cell line (COLO 205) by heat-stable enterotoxin of Escherichia coli. Biochimica et Biophysica Acta.1403 (1): 1-4.

63)   Chakrabarti, M.K., Bhattacharya, J., Bhattacharya, M.K., Nair, G.B., Bhattacharya, S.K., Mahalanabis. D. (1999). Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis. Acta Paediatr. 88 (2): 161-5.

64)   Chaudhuri, A.G., Bhattacharya, J., Nair, G.B., Takeda, T. and Chakrabarti, M.K. (1998). Rise of cytosolic Ca2+ and activation of membrane-bound guanylyl cyclase activity in rat enterocytes by heat-stable enterotoxin of Vibrio cholerae non-01. FEMS Microbiology Letters. 1998 160(1): 125-9.

65)   Bhattacharya, J., Chaudhuri AG, Sinha AK, Samanta AK, Chakrabarti MK. (1997) Binding of Escherichia coli heat-stable enterotoxin and rise of cyclic GMP in COLO 205 human colonic carcinoma cells. FEMS Microbiology Letters; 156 (1): 79-83.

66)   Chakrabarti, M.K., Bhattacharya, M.K, Bhattacharya, J., Bhattacharya, S.K., and Mahalanabis, D. (1998). Evaluation of different antibiotics in inhibiting colonization of Vibrio cholerae O1 and O139 in the rabbit intestine. Chemotherapy. 44(2): 108-11.

67)   Chakrabarti, M.K. and Bhattacharya, J. (1996). Cyclic 3’ 5’ adenosine monophosphate in bacteria. Indian Journal of Physiology and Allied Science, 50: 128-135.

68)   Chakrabarti, M. K., Bhattacharya, J., Sinha, A.K., De, S.P. (1995). Role of outer membrane proteins on the adherence of Vibrio parahaemolyticus to rabbit intestinal epithelial cell in vitro. International Journal of Medical Microbiology. 282(4): 436-41.

69)   Chakrabarti, M.K., Bhattacharya, J. and De, S.P. (1995). Hemagglutinating activities of different strains of Vibrio parahaemolyticus. Medical Science Research 23: 497-498.

1.     Ambrose CS, Bhattacharya J, Fox CB, McIntosh ED, Stern PL. Therapeutic Advances in Vaccines. 2013 SAGE Publication, London, UK. May; 1(1):3-5. doi: 10.1177/2051013613486264.

2.     Bhattacharya, Jayanta. Unconventional technologies accelerating HIV Vaccine Discovery. Spinco Biotech CuttingEdge Newsletter. September 2015: page 22-24.

1.     International Patent Application Filed by THSTI & IAVI

Partners: THSTI, IAVI,

Name of the Invention: Potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant

International Patent Application No: PCT/IB2022/057923

Filing date: 24 August 2022

Filed to: International Bureau of WIPO

Inventors: Jayanta Bhattacharya (corresponding lead PI), Nitin Hingankar, Payel Das, Suprit Deshpande, Pallavi Kshetrapal, Ramachandran Thiruvengadam, Amit Awasthi, Zaigham Abbas Rizvi

2.     South Africa Patent granted

              Partners: THSTI, IAVI, YRGCARE

              Name of the Invention: Engineered HIV-1 envelope immunogen

             SOUTH AFRICAN PATENT grant NO: 2020/05470

              Grant date: 30 March 2022

Inventors: J. Bhattacharya (IAVI), R. Kumar (THSTI), S. Deshpande (THSTI), V. Kumar (THSTI), K.G Murugavel (YRGCARE)

3.     Provisional Patent Application Filed by THSTI

Partners: THSTI, YRGCARE

Application reference number: 201611004727

Name of the invention: ISOLATED NUCLEOTIDE SEQUENCE USEFUL FOR THE PREVENTION OF HIV-1 INFECTION

      Filing date:  February 10, 2016

Inventors: Jayanta Bhattacharya (IAVI), Suprit Deshpande (THSTI), Shilpa Patil (THSTI), Rajesh Kumar (THSTI), K.G. Murugavel (THSTI)

4.     Provisional Patent Application Filed by THSTI

Partners: THSTI, IAVI

Application reference No: 201711016548

Filing date: 

Name of the invention: Engineered Recombinant Protein Antigen of Trimeric Mimic of HIV-1 Envelope Glycoprotein Spike

Filing date: 2017

Inventors: Jayanta Bhattacharya (IAVI), Rajesh Kumar (THSTI), Vivek Kumar Yadav (THSTI), Shilpa Patil (THSTI)

5.     International Publication Reference No: WO 2017/007646 Al

Partners: THSTI, IAVI

International Publication Reference No: WO 2017/007646 Al

International Publication Date: 12 January 2017

Name of the invention: HIV-1 CLADE C ENVELOPE GLYCOPROTEINS

Filing date: 29 June 2016

International application ref no: PCT/US2016/039936

Inventors: Jayanta Bhattacharya (IAVI), Suprit Deshpande (THSTI), Shilpa Patil (THSTI), Bimal K Chakrabarti (IAVI)

6.     International Publication Reference No: WO 2016/065252 A2

Partners: THSTI, IAVI

International Publication Reference No: WO 2016/065252 A2

International Publication Date: 28 April 2016

Name of the invention: NATIVE TRIMERIC ENV IMMUNOGEN DESIGN

Filing date: 23 October 2015

International application ref no: PCT/US20 15/057098

Inventors: Bimal K Chakrabarti (IAVI), Saikat Boliar (THSTI), Supratik Das (THSTI), Tripti Srivastava (THSTI), Charles Richter King (IAVI), Jayanta Bhattacharya (IAVI), Sweety Samal (THSTI)

1)     WHO CoViNet global reference center program (THSTI)

Role: Principal Investigator

Period -2024 (new grant)

2)     National BSL-3 Laboratory Network (THSTI component) under National One Health Mission

Role: Principal Investigator

Period – 2024 onward

3)     Inter-Institutional School Diagnostic Innovation in Bio-Design: A fellowship Program for building next generation pool of diagnostic innovators and entrepreneurs

            Role: Principal Investigator

            Period: June 2023-March 2024

            Sanctioned Funding amount: INR 9.58 crores; Period: 2023-2028

4)     Indian Council of Medical Research:Evaluation of the magnitude, kinetics and longevity of humoral and cellular immune

            responses to SARS-CoV-2 variants in vaccinated and naturally infected individuals.

            Role: Lead PI & Project Coordinator; AIIMS PIs: Prof Randeep Guleria & Prof Anant Mohan

            Type: Multicentric Project (THSTI, AIIMS); Lead Institute: THSTI

            Awarded Year: 2022; Funding Period: 2022-2024

            Funding Amount: INR 1.3 crores

5)     Bill & Melinda Gates Foundation (BMGF): Global Immunology & Immune Sequencing for Epidemic Response (GIISER South Asia).

            Role: Principal Investigator & Lead, Monoclonal Ab discovery & development component

            Type: Multicentric Project (THSTI & IGIB)

            Awarded Year: October 2021; Funding Period: 2021-2025

            Funding Amount: $1,335,437

6)     USAID (United States Agency for International Development) through IAVI: Accelerating the Development of Vaccines and New Technologies to Combat the AIDS Epidemic (ADVANCE) through South-South Collaboration.

            Role: Lead PI (India, THSTI)

            Type: Multicentric Project (THSTI, YRGCARE & African partners at UVRI, KEMRI, UKZN, NICD, AHRI, HIL-Imperial College)

            Awarded Year: January 2021-2025; Funding Period: 2022-2022

            Funding Amount: USD 100,000/year

7)     Department of Biotechnology, (Development of therapeutic broadly neutralizing monoclonal antibodies against circulating HIV-1 clade C in children and adults")

            Role: Lead PI and Project Coordinator

            Type: Multicentric Project (THSTI, AIIMS, IISc, CSTM, IGICH, JNIMS, NIRT, NARI)

            Awarded Year: Approved,

            Funding Amount: INR 799.93 lakhs

8)     Wellcome Trust-DBT India Alliance Team Science Grant (TSG).Developing broadly neutralizing monoclonal antibody mediated prevention and treatment strategy by assessing their effectiveness in neutralizing HIV‐1 subtype C circulating in India across different regions and distinct risk groups.

            Role: Lead PI

            Partner Institutions: ICMR-NIRRH (PI: Dr V Patel), Mumbai and YRGCARE (PI: Dr S Saravanan), Chennai

Collaborators (India): Nair Hospital, Mumbai (West); Calcutta School of Tropical Medicine (East), YRGCARE CRC network (South, North-East, Central)

Collaborators (Global): Dr David Montefiori (Duke University, Durham, NC, USA) and IAVI Neutralizing Antibody Center, TSRI, La Jolla, California, USA

            Awarded Year(2019). Funding period: 2020-2025; Funding Amount: INR ~ 9,21,17,530

9)     Science & Engineering Research Board (SERB).Department of Science & Technology, Identification, characterization and optimization of monoclonal antibodies that broadly neutralize entry of HIV-1 subtype C predominantly circulating in India.

            Role: PI;

            Awarded Year(2019). Funding period: 2020-2023; Funding Amount: INR 55,67,220/-

10)   The Research Council of Norway. GLOBVAC (Global Health & Vaccination Research), (a tripartite collaboration between University of Oslo, Neutralizing Antibody Center, International AIDS Vaccine Initiative at The Scripps Research Institute, La Jolla, California, USA and Translational Health Science & Technology Institute, DBT, India), “Developing HIV broadly neutralizing antibodies as a prevention product for global access through antibody half-life extension engineering”.

            Role: Co-PI (THSTI site);

            Awarded Year: 2019, Funding period: 2019-2022; Funded Amount: 75,06,000 NOK (INR ~ 5,93,13,786).

11)   Department of Biotechnology, Govt of India.  “Indo-European Consortium for Next Generation Influenza Vaccine Innovation” under Horizon 2020 program

            Role: Co-investigator       

            Awarded Year: 2019, Funding period: 2020-2025

Collaborating Institutions from 19 Partnering Countries (India [NII, THSTI, PHFI, IIT-M, KEM], Germany, Belgium, Norway,      France, Spain, USA, Netherlands.

12)   Department of Biotechnology & Department of Science & Technology (under Indo-South Africa joint proposal). Isolation and Characterization of Monoclonal Antibodies from HIV-1 Subtype C Infected Individuals.

            Role: PI & Program Coordinator (India) (South Africa PI: Prof Lynn Morris):

            AWARDED Year: December 2017. Total Awarded Amount: INR 2,04,64,636.

13)   Department of Biotechnology. National Bioscience Award Project Status: Completed.

            Role: PI. Period: 2014-2017 Awarded Amount: INR 15, 00,000 (3 Years).

14)   Department of Biotechnology. “Construction and Characterization of Genetically Engineered Chimeric HIV-1 Envelope Protein Modulating Virus Neutralization: Implication and Relevance in Vaccine development”Status: Completed.

            Role: PI. Awarded amount: INR 53.87 Lacs. Period: 2010-2013.

15)   Department of Science and Technology (under IBSA Program). “Identification of neutralizing antibody epitopes on Indian and South African HIV-1 subtype C viruses for HIV vaccine design”.Status: Completed

Role: PI; Awardedamount: > INR 136 Lacs. Period: 2011-2014, Type: Multi-centric collaborative project between Indian institutes (NARI, AIIMS, ICGEB, YRGCARE) and South Africa (NICD, Johannesburg).

16)   NIH Fogarty funded Vanderbilt NARI-NIE-Informatics Training Program (VNNIT) [1D43TW008440-01]. Role: Co-Principal Investigator (PI: Dr S M Mehendale).

17)   Department of Biotechnology / Indian Council of Medical Research (DBT/ICMR)[2006-2010]. Neutralization Epitope Mapping in HIV-1 Envelope of Indian Origin and Construction of Envelope- Based Peptide Immunogen for Generation of Broadly Cross-Reactive Neutralizing Antibodies. Role: Principal Investigator Status: Completed. Awarded amount: INR 54 Lakhs.

18)   Department of Biotechnology/Indian Council of Medical Research (DBT/ICMR)[2006-2010]. Comprehensive molecular analysis of HIV incidence, genetic diversity and anti-retroviral drug-resistance mutations in diverse risk groups across wide geographic locales of India. Role: PI, Status: Completed Awarded amount: INR 75 Lakhs.

19)   Department of Biotechnology/Indian Council of Medical Research (DBT/ICMR)[2006-2010]. Establishment of virtual knowledge and resource center for reagents, protocols and technology in context with research in HIV and AIDS.

            Role: PI & Project Coordinator; Status: Completed Awarded amount: INR 9.92 Lakhs.

20)   Collaboration of Vaccine Development-Vaccine Immune Monitoring Consortium (CAVD/VIMC): Funded by Bill and Melinda Gates Foundation: Role: Co-investigator, India site (PI: David Montefiori, Duke University) Status:Completed.

21)   American Foundation of AIDS Research (amfAR), New York, USA [2004-2006]. Role: Principal Investigator Status: Completed; Awarded amount: US$ 99,000.

1.     Reviewer (2019), Scheme for Transformational and Advanced Research in Sciences (STARS), Ministry of Human Resource Development (MHRD), Department of Higher Education Science Bureau, Govt of India, being implemented by the Indian Institute of Science, Bengaluru, Karnataka 560012.

2.     Member, IAVI global key influencer (2018-2019)

3.     MVP Award from the International AIDS Vaccine Initiative, New York, USA, July 2018

4.     MVP Award from the International AIDS Vaccine Initiative, New York, USA, October 2017

5.   ‘On the Spot Award of Excellence’, by the International AIDS Vaccine Initiative, New York, USA, February, 2015

6.   Member, National Academy of Science (MNASc.), India (Allahabad), 2014.

7.   National Bioscience Award for Career Development, 2013, Ministry of Science and Technology, Govt. of India.

8.   Member, DBT Infectious Disease Biology Task Force (2012-2013)

9.   Chairperson, IMAPAC 5th Annual Vaccine World India Summit, Pune, March 2015

10.   International Travel Award/Fellowship: International AIDS Vaccine Conference, Cape Town, South Africa, 2008.

11.   Visiting Scholar, Duke University, Durham, North Carolina, USA (July-August, 2007)

12.   Research Fellowship Grant Award from The American Foundation for AIDS Research (amfAR), USA, 2004-2006.

13.   UNESCO-ASM Visiting Resource Person Program Award, 2005.

14.   Travel Grant Award 11^th Conference on Retrovirus & Opportunistic infection, San Francisco, CA, USA 2004.

15.   Travel Grant Award 12^th Conference on Retrovirus & Opportunistic infection, Boston, MA, USA, 2005

16.   Prof. P.B. Sen Memorial award from The Physiological Society of India (1998).

17.   Senior and Junior Research Fellowships from Indian Council of Medical Research (1993-1998).

18.   Prof Arun Sen Award for ranking FIRST in B.Sc. (Honors), Burdwan University, 1989.

Member of Professional Bodies

1. Member, National Academy of Sciences, Allahabad, India
2. Past Member, Task Force (Infectious Disease Biology Study Section), Department of Biotechnology, Govt of India
3. Member, Scientific Advisory Board, Premier Medical Corporation Ltd., Nani Daman, Gujarat.
4. Member, American Society of Microbiology
5. Life member, Physiological Society of India

Editorial Board Member

1. Academic Editor and Member of the Editorial Board, PLoS One.
2. Associate Editor & Senior Editorial Management Team, Therapeutic Advances in Vaccines, SAGE Publications Ltd, London, UK
3. Member, Editorial Board of World Journal of Virology, Baishideng Publishing Group.
4. Section Editor & Senior Editorial Board Member, VirusDisease, Springer Publications Inc.

IAVI investigators:

1. Dr Ranajoy Mullick

2. Dr Jyoti Sutar

3. Dr Sohini Mukherjee

4. Dr K Varsha Mohan